Navigation Links
Suppression of Enzyme Delays a Type of Breast Cancer

Canadian researchers have disclosed that suppression of an enzyme called PTP1B stalls the advancement of a specific type of breast cancer//. This study was conducted on laboratory mice which were genetically modified to develop into a breast cancer condition of humans.

This research headed by Michel L.Tremblay along with Sophie Julien of McGill cancer Center, Quebec delayed the advancement of a particular kind of breast cancer linked to ERBB2 gene. In this case, the breast tumor appeared almost eight weeks later and lung metastases did not happen. In some mice cancer did not develop at all.

On the other hand, when the enzyme PTP1B was expressed it resulted in the development of cancer. Understanding of the relationship between this enzyme and breast cancer is likely to go a long way in treatment of this disease.

Clinical trials of a drug with inhibitory reaction to this protein are underway. There is already a research finding which claims that diabetes 2 and obesity can be treated by this enzyme suppression. In addition to this, PTP1B inhibitors have been developed by drug companies too.

Testing of this inhibitor on humans could begin by 2008. These inhibitors alone or along with another drug could be used in the treatment of breast cancer patients. Currently Herceptin or Trastuzumab is being used.

According to these scientists though there is lot of work to be done in this field, this finding is sure to have a positive impact on further research in this topic.


JYT
'"/>




Page: 1

Related medicine news :

1. Adrenal Suppression not predicted by inhaled corticosteroids
2. Transplant Cures Rats’ Type 2 Diabetes without Need for Immune Suppression Drug
3. Long-time Gastric Acid Suppression Does Not Increase The Risk Of Cancer
4. Should Menstrual Suppression Be a Lifestyle Choice?
5. Enzyme may be target for obesity drugs
6. Researchers trick Alzheimers Enzyme
7. Enzyme stimulates growth of adult stem cells
8. Enzyme may aid hold back disease
9. Enzyme help destroy cancer cell
10. Enzyme Associated with Memory
11. Enzyme Associated With Memory
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... , ... “America On The Brink”: the Christian history of the United States ... creation of published author, William Nowers. Captain Nowers and his wife, Millie, have ... thirty years in the Navy. Following his career as a naval aviator and ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of ... Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, ... In honor of Morris F. Collen, a pioneer in the field of medical informatics, ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017 Diplomat Pharmacy, ... 8th Day Software and Consulting, LLC , and named ... 8th Day Software, based in Tennessee , ... 8th Day expands EnvoyHealth,s service offerings for health care ... "In an interoperable ...
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host ... webcast on Friday, November 3, 2017, beginning at 7:00 ... approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... performance and guidance for 2018, Hill-Rom executives will also ... performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
Breaking Medicine Technology: